WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
CN104761637B
(zh)
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
TWI464262B
(zh)
|
2007-09-26 |
2014-12-11 |
中外製藥股份有限公司 |
抗體固定區的變異
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
EP2481752B1
(en)
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
MX353144B
(es)
*
|
2010-04-20 |
2017-12-20 |
Genmab As |
Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
|
AU2011257121A1
(en)
|
2010-05-27 |
2013-01-10 |
Genmab A/S |
Monoclonal antibodies against HER2
|
HUE038305T2
(hu)
|
2010-11-17 |
2018-10-29 |
Chugai Pharmaceutical Co Ltd |
A VIII vérkoagulációs faktor mûködésére alternatív funkciójú multispecifikus antigén-kötõ molekula
|
WO2013004841A1
(en)
|
2011-07-06 |
2013-01-10 |
Genmab A/S |
Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
|
EP2771364B1
(en)
|
2011-10-27 |
2019-05-22 |
Genmab A/S |
Production of heterodimeric proteins
|
CA2853230C
(en)
|
2011-10-31 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
WO2013063702A1
(en)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
EP3401337A1
(en)
*
|
2012-09-25 |
2018-11-14 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
CA3206122A1
(en)
|
2012-11-28 |
2014-06-05 |
Zymeworks Bc Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
RU2687043C2
(ru)
*
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
SG11201508911PA
(en)
*
|
2013-04-29 |
2015-11-27 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
AU2014286116A1
(en)
|
2013-07-05 |
2016-02-04 |
Genmab A/S |
Humanized or chimeric CD3 antibodies
|
KR102441231B1
(ko)
*
|
2013-09-27 |
2022-09-06 |
추가이 세이야쿠 가부시키가이샤 |
폴리펩티드 이종 다량체의 제조방법
|
AP2016009222A0
(en)
|
2013-11-04 |
2016-05-31 |
Glenmark Pharmaceuticals Sa |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
CA2930285A1
(en)
|
2013-11-21 |
2015-05-28 |
Apeiron Biologics Ag |
Preparations and methods for treating a gd2 positive cancer
|
US9840566B2
(en)
|
2013-11-21 |
2017-12-12 |
Apeiron Biologics Ag |
Preparations and methods for treating a GD2 positive cancer
|
CN105899534B
(zh)
|
2014-01-15 |
2020-01-07 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
CA2932364A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with improved protein a-binding
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
LT3116909T
(lt)
|
2014-03-14 |
2020-02-10 |
Novartis Ag |
Antikūno molekulės prieš lag-3 ir jų panaudojimas
|
EP3119423B1
(en)
|
2014-03-15 |
2022-12-14 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
EP3107938B1
(en)
|
2014-05-28 |
2022-05-04 |
Zymeworks Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
US10647777B2
(en)
*
|
2014-05-28 |
2020-05-12 |
Genzyme Corporation |
Methods of controlling the formation of disulfide bonds in protein solutions
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
EP3172237A2
(en)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
ES2805475T3
(es)
|
2014-07-21 |
2021-02-12 |
Novartis Ag |
Tratamiento del cáncer utilizando un receptor antigénico quimérico de CD33
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
JP6956630B2
(ja)
|
2014-07-24 |
2021-11-02 |
ジェネンテック, インコーポレイテッド |
薬剤の少なくとも1つのトリスルフィド結合を含むタンパク質中のチオール部分へのコンジュゲーション方法
|
US10329323B2
(en)
|
2014-07-25 |
2019-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Method for purifying antibodies using PBS
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
MX2017003645A
(es)
|
2014-09-17 |
2017-05-30 |
Novartis Ag |
Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
PE20171067A1
(es)
|
2014-10-14 |
2017-07-24 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
ES2772348T3
(es)
|
2014-12-19 |
2020-07-07 |
Ablynx Nv |
Dímeros de Nanobody con uniones cisteína
|
US10865253B2
(en)
|
2014-12-19 |
2020-12-15 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
AR103172A1
(es)
*
|
2014-12-22 |
2017-04-19 |
Novartis Ag |
Reducción selectiva de residuos de cisteina en anticuerpos il-17
|
JP6894375B2
(ja)
*
|
2015-02-05 |
2021-06-30 |
アブリンクス エン.ヴェー. |
C末端で操作されたシステインを介して連結されたNanobodyダイマー
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
US10253086B2
(en)
|
2015-04-08 |
2019-04-09 |
Novartis Ag |
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
|
JP6962819B2
(ja)
|
2015-04-10 |
2021-11-05 |
アディマブ, エルエルシー |
親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
JP7103751B6
(ja)
*
|
2015-04-28 |
2022-08-15 |
ザイムワークス,インコーポレイテッド |
修飾された抗原結合ポリペプチド構築物及びその使用
|
EA201890305A1
(ru)
|
2015-07-15 |
2018-07-31 |
Генмаб А/С |
Гуманизированные или химерные cd3-антитела
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
EA201890296A1
(ru)
|
2015-07-30 |
2018-08-31 |
Макродженикс, Инк. |
Pd-1-связывающие молекулы и способы их применения
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GEP20217328B
(en)
|
2015-12-14 |
2021-12-10 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
KR20180094977A
(ko)
|
2015-12-17 |
2018-08-24 |
노파르티스 아게 |
c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
CN105420209A
(zh)
*
|
2015-12-30 |
2016-03-23 |
海口奇力制药股份有限公司 |
一种制备rhCNB二聚体的方法
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
RU2018134771A
(ru)
|
2016-03-04 |
2020-04-06 |
Новартис Аг |
Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
THERAPEUTIC MEDICINE INDUCING CELLULAR INJURY FOR USE IN THE TREATMENT OF CANCER
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
ES2944607T3
(es)
|
2016-04-15 |
2023-06-22 |
Novartis Ag |
Composiciones y métodos para la expresión selectiva de receptores quiméricos para el antígeno
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
CN109311948B
(zh)
|
2016-05-11 |
2022-09-16 |
思拓凡生物工艺研发有限公司 |
清洁和/或消毒分离基质的方法
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
US10513537B2
(en)
|
2016-05-11 |
2019-12-24 |
Ge Healthcare Bioprocess R&D Ab |
Separation matrix
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
JP7106187B2
(ja)
|
2016-05-11 |
2022-07-26 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックスを保存する方法
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
CA3025162A1
(en)
|
2016-05-26 |
2017-11-30 |
Qilu Puget Sound Biotherapeutics Corporation |
Mixtures of antibodies
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
WO2017212071A1
(en)
*
|
2016-06-10 |
2017-12-14 |
Lonza Ltd |
Method for stabilizing proteins
|
BR112019000512A2
(pt)
|
2016-07-14 |
2019-04-24 |
Genmab A/S |
anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
|
JP7219376B2
(ja)
|
2016-07-15 |
2023-02-08 |
ノバルティス アーゲー |
キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
|
BR112019001138A2
(pt)
*
|
2016-07-19 |
2019-04-30 |
Ibentrus, Inc. |
proteínas biespecíficas e métodos para preparar as mesmas
|
KR20190034588A
(ko)
|
2016-07-28 |
2019-04-02 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
CN110267677A
(zh)
|
2016-08-01 |
2019-09-20 |
诺华股份有限公司 |
使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
|
BR112019006074A2
(pt)
*
|
2016-09-29 |
2019-06-18 |
Beijing Hanmi Pharmaceutical Co Ltd |
heterodímero, método de produção do heterodímero, métodos de produção de um heterodímero, ácido nucleico, vetor ou sistema de vetores, célula, composição farmacêutica e método de tratamento ou prevenção de uma doença ou distúrbio em um sujeito em necessidade do mesmo
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
EP3533804A4
(en)
|
2016-11-18 |
2020-06-17 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF
|
EP3544724A4
(en)
|
2016-11-22 |
2020-10-14 |
Elektrofi, Inc |
PARTICLES INCLUDING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND THEIR METHODS OF USE
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
EP3589650A1
(en)
|
2017-03-02 |
2020-01-08 |
Novartis AG |
Engineered heterodimeric proteins
|
EP3592769A1
(en)
|
2017-03-09 |
2020-01-15 |
Genmab A/S |
Antibodies against pd-l1
|
CA3057907A1
(en)
|
2017-03-31 |
2018-10-04 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
WO2018177324A1
(zh)
*
|
2017-04-01 |
2018-10-04 |
北京韩美药品有限公司 |
抗pd‐l1/抗pd‐1天然抗体结构样异源二聚体形式双特异抗体及其制备
|
KR20200020662A
(ko)
|
2017-04-03 |
2020-02-26 |
온콜로지, 인크. |
면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
CN110831965B
(zh)
|
2017-06-21 |
2023-03-07 |
吉利德科学公司 |
靶向hiv gp120和cd3的多特异性抗体
|
PE20200717A1
(es)
|
2017-06-22 |
2020-07-21 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
TWI820031B
(zh)
|
2017-07-11 |
2023-11-01 |
美商坎伯斯治療有限責任公司 |
結合人類cd137之促效劑抗體及其用途
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗lag−3抗体の投薬量レジメンおよびその使用
|
CN116333131A
(zh)
|
2017-08-04 |
2023-06-27 |
健玛保 |
与pd-l1和cd137结合的结合剂及其用途
|
BR112020003670A2
(pt)
|
2017-08-22 |
2020-09-01 |
Sanabio, Llc |
receptores de interferon solúveis e usos dos mesmos
|
TW201932142A
(zh)
|
2017-10-20 |
2019-08-16 |
瑞士商赫孚孟拉羅股份公司 |
自單特異性抗體產生多特異性抗體之方法
|
MX2020004100A
(es)
|
2017-10-30 |
2020-07-24 |
Hoffmann La Roche |
Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
WO2019153200A1
(zh)
*
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
EP3750920A4
(en)
*
|
2018-02-11 |
2021-11-10 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
BISPECIFIC ANTIBODY IN HETERODIMER FORM SIMILAR TO A NATURAL ANTI-PD-1 / ANTI-VEGF ANTIBODY STRUCTURE AND PRODUCTION OF IT
|
CN111971298A
(zh)
|
2018-03-12 |
2020-11-20 |
健玛保 |
抗体
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
CN112368019A
(zh)
|
2018-05-16 |
2021-02-12 |
詹森生物科技公司 |
治疗癌症并增强t细胞重定向治疗剂的功效的方法
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
CN108640997A
(zh)
*
|
2018-05-22 |
2018-10-12 |
蔡毓旻 |
一种双特异性抗体
|
US20210220289A1
(en)
*
|
2018-05-24 |
2021-07-22 |
Elektrofi, Inc. |
Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
TW202016136A
(zh)
|
2018-06-01 |
2020-05-01 |
瑞士商諾華公司 |
針對bcma之結合分子及其用途
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
MX2020013443A
(es)
|
2018-06-13 |
2021-02-26 |
Novartis Ag |
Receptores de antigeno quimerico de bcma y usos de los mismos.
|
US20210238268A1
(en)
|
2018-06-19 |
2021-08-05 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
KR20210116429A
(ko)
|
2018-10-04 |
2021-09-27 |
젠맵 홀딩 비.브이. |
이중특이적 항-cd37 항체를 포함하는 제약 조성물
|
CN113454111A
(zh)
|
2018-11-06 |
2021-09-28 |
健玛保 |
抗体配制剂
|
CA3119161A1
(en)
|
2018-11-13 |
2020-05-22 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
TW202043268A
(zh)
*
|
2018-12-18 |
2020-12-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
JP2022513255A
(ja)
|
2018-12-20 |
2022-02-07 |
ノバルティス アーゲー |
HDM2-p53相互作用阻害剤とBCL2阻害剤との組み合わせ及び癌を処置するためのその使用
|
EP3897637A1
(en)
|
2018-12-20 |
2021-10-27 |
Novartis AG |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
SG11202106895UA
(en)
*
|
2019-01-07 |
2021-07-29 |
Shattuck Labs Inc |
Heterodimeric proteins for modulating gamma delta t cells
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
AU2020214626A1
(en)
|
2019-01-31 |
2021-09-16 |
Elektrofi, Inc. |
Particle formation and morphology
|
CN113329792A
(zh)
|
2019-02-15 |
2021-08-31 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
EA202192019A1
(ru)
|
2019-02-15 |
2021-11-02 |
Новартис Аг |
Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
MA55519A
(fr)
|
2019-03-29 |
2022-02-09 |
Atarga Llc |
Anticorps anti-fgf23
|
US20230071196A1
(en)
|
2019-05-21 |
2023-03-09 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
AU2020279224A1
(en)
|
2019-05-21 |
2021-12-16 |
Novartis Ag |
Trispecific binding molecules against BCMA and uses thereof
|
US20210139585A1
(en)
|
2019-05-21 |
2021-05-13 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
SG11202112926YA
(en)
|
2019-05-30 |
2021-12-30 |
Amgen Inc |
Engineering the hinge region to drive antibody dimerization
|
WO2021019389A1
(en)
|
2019-07-26 |
2021-02-04 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
AU2020329217A1
(en)
|
2019-08-12 |
2022-07-28 |
Aptevo Research And Development Llc |
4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
|
EP4013783A1
(en)
|
2019-08-15 |
2022-06-22 |
Janssen Biotech, Inc. |
Materials and methods for improved single chain variable fragments
|
US20230257479A1
(en)
|
2019-09-12 |
2023-08-17 |
Genmab A/S |
Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
|
EP4027978A1
(en)
|
2019-09-13 |
2022-07-20 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
JP2022553306A
(ja)
|
2019-10-21 |
2022-12-22 |
ノバルティス アーゲー |
Tim-3阻害剤およびその使用
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
CA3167413A1
(en)
|
2020-01-17 |
2021-07-22 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
CN115298322A
(zh)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
用于单细胞分泌组学的方法和组合物
|
WO2021148006A1
(en)
*
|
2020-01-23 |
2021-07-29 |
Adagene Ag |
Heterodimeric proteins with fc mutations
|
KR20220144377A
(ko)
|
2020-01-30 |
2022-10-26 |
우모자 바이오파마 인코포레이티드 |
이중특이적 형질도입 촉진제
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
IL296263A
(en)
|
2020-03-13 |
2022-11-01 |
Janssen Biotech Inc |
Materials and methods for ligation of siglec-3/cd33
|
PE20230444A1
(es)
|
2020-03-18 |
2023-03-08 |
Genmab As |
Anticuerpos
|
US20230128499A1
(en)
|
2020-03-27 |
2023-04-27 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
CN115916166A
(zh)
|
2020-05-08 |
2023-04-04 |
健玛保 |
针对cd3和cd20的双特异性抗体
|
AU2021281134A1
(en)
|
2020-05-27 |
2023-02-09 |
Janssen Biotech, Inc. |
Proteins comprising CD3 antigen binding domains and uses thereof
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
EP4182025A1
(en)
|
2020-07-16 |
2023-05-24 |
Novartis AG |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
CA3190307A1
(en)
|
2020-07-29 |
2022-02-03 |
Janssen Biotech, Inc. |
Proteins comprising hla-g antigen binding domains and their uses
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
EP4192859A1
(en)
|
2020-08-06 |
2023-06-14 |
BioNTech SE |
Binding agents for coronavirus s protein
|
CA3191710A1
(en)
|
2020-08-20 |
2022-02-24 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
JP2023542092A
(ja)
|
2020-09-10 |
2023-10-05 |
ジェンマブ エー/エス |
びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
|
JP2023542289A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー/エス |
濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
|
IL301102A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
CN116437956A
(zh)
|
2020-09-10 |
2023-07-14 |
健玛保 |
用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
|
MX2023002545A
(es)
|
2020-09-10 |
2023-03-14 |
Genmab As |
Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para el tratamiento de linfoma difuso de celulas b grandes.
|
KR20230066391A
(ko)
|
2020-09-10 |
2023-05-15 |
젠맵 에이/에스 |
여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
EP4221742A1
(en)
|
2020-10-02 |
2023-08-09 |
Genmab A/S |
Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
|
US20230374162A1
(en)
|
2020-10-07 |
2023-11-23 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
KR20230086765A
(ko)
|
2020-10-13 |
2023-06-15 |
얀센 바이오테크 인코포레이티드 |
분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
|
EP4229086A1
(en)
|
2020-10-15 |
2023-08-23 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
JP2023548034A
(ja)
|
2020-10-22 |
2023-11-15 |
ヤンセン バイオテツク,インコーポレーテツド |
デルタ様リガンド3(dll3)抗原結合ドメインを含むタンパク質及びその使用
|
EP4240765A2
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Antibody fc variants
|
WO2022097061A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
JP2023548595A
(ja)
|
2020-11-10 |
2023-11-17 |
アムジエン・インコーポレーテツド |
多重特異性抗原結合ドメインの新規のリンカー
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
CA3200314A1
(en)
|
2020-12-01 |
2022-06-09 |
Peter Pavlik |
Tumor-associated antigens and cd-3 binding proteins, related compositions, and methods
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
CA3214307A1
(en)
|
2021-03-24 |
2022-09-29 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
JP2024512035A
(ja)
|
2021-03-24 |
2024-03-18 |
ヤンセン バイオテツク,インコーポレーテツド |
Cd22及びcd79bを標的とする抗体
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
EP4334359A1
(en)
|
2021-05-07 |
2024-03-13 |
Genmab A/S |
Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
TW202313684A
(zh)
|
2021-06-04 |
2023-04-01 |
美商安進公司 |
抗ccr8抗體及其用途
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
IL309319A
(en)
|
2021-06-21 |
2024-02-01 |
Genmab As |
Combined dosage regimen CD137 and PD-L1 binding agents
|
WO2023037333A1
(en)
|
2021-09-13 |
2023-03-16 |
Janssen Biotech, Inc |
CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
AR127298A1
(es)
|
2021-10-08 |
2024-01-10 |
Genmab As |
Anticuerpos que se unen a cd30 y cd3
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023089587A1
(en)
|
2021-11-22 |
2023-05-25 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
WO2023144290A1
(en)
|
2022-01-28 |
2023-08-03 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
US20230303693A1
(en)
|
2022-01-28 |
2023-09-28 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
WO2023180346A1
(en)
|
2022-03-22 |
2023-09-28 |
Morphosys Ag |
Deimmunized antibodies specific for cd3
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|